Knee Pain2
Knee Pain2

Reduced pain associated with 5 activities2
The effectiveness and safety of EUFLEXXA was shown to be comparable to another HA product* in a head-to-head clinical trial. The study was conducted in 321 patients with OA knee pain over a 12-week period.

  • After 3 injections, patients had less pain when climbing stairs, walking, standing, sitting, and rest during the night
  • Pain improvement with EUFLEXXA was 62% (P<0.0001) vs 55% with the other product (P<0.0001)

Did You Know?
The average American takes about 5,900 steps every day.3

In the 12-week study, side effects caused by EUFLEXXA were joint pain (11/160), increase in blood pressure (3/160), joint swelling (3/160), feeling of sickness (3/160), tingling (2/160), back pain (1/160), nausea (1/160), skin irritation (1/160), and tenderness in study knee (1/160).4

*In comparison to Synvisc.

Questions based on the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC). WOMAC is an internationally recognized and widely used set of standardized questionnaires used by health care professionals to assess the condition of patients with osteoarthritis of the knee and hip. Measures include pain, stiffness, and physical functioning of the joints.5

Improvements from baseline were statistically significant for both treatment groups.

Next, find out more about how people have less need for simple pain medications when on EUFLEXXA

Please See Important Safety Information and Full Prescribing Information.


EUFLEXXA (1% sodium hyaluronate) is used to relieve knee pain due to osteoarthritis. It is used for patients who do not get enough relief from simple pain medications such as acetaminophen or from exercise and physical therapy.

EUFLEXXA is only for injection into the knee, performed by a doctor or other qualified healthcare professional.


  • Do not take this product if you have had any previous allergic reaction to EUFLEXXA or hyaluronan products.
  • You should not have EUFLEXXA injected into the knee if you have a knee joint infection or skin diseases or infections around the injection site.
  • EUFLEXXA has not been tested in pregnant women, women who are nursing or in children less than 18 years of age. After you receive your EUFLEXXA injection you should avoid physical activities for 48 hours such as jogging, tennis, heavy lifting, or standing on your feet for a long time (more than one hour at a time).
  • The most common adverse events related to EUFLEXXA injections were joint pain, back pain, limb pain, muscle pain, and joint swelling.

You are encouraged to report negative side effects of prescription drugs to the FDA.
Visit or call 1-800-FDA-1088.
You may also contact Ferring Pharmaceuticals Inc. at 1-888-FERRING.